A multi-centre, double-blind, randomized, placebo-controlled trial to evaluate the effectiveness and safety of ramelteon for the prevention of postoperative delirium in elderly cancer patients: a study protocol for JORTC-PON2/J-SUPPORT2103/NCCH2103

被引：1

作者：

Sadahiro, Ryoichi ^{[1
]}

Hatta, Kotaro ^{[2
]}

Yamaguchi, Takuhiro ^{[3
]}

Masanori, Enokido ^{[4
]}

Matsuda, Yoshinobu ^{[5
]}

Ogawa, Asao ^{[4
]}

Iwata, Yusei ^{[4
]}

Tokoro, Akihiro ^{[5
]}

Nakahara, Rika ^{[1
]}

Hirayama, Takatoshi ^{[1
]}

Yanai, Yuko ^{[1
]}

Ogawa, Yuko ^{[1
]}

Kayano, Ayako ^{[1
]}

Ariyoshi, Keisuke ^{[6
]}

Oyamada, Shunsuke ^{[6
]}

Uchitomi, Yosuke ^{[7
]}

Akechi, Tatsuo ^{[8
]}

Yamamoto, Noboru ^{[9
]}

Okita, Natsuko ^{[10
]}

Yorikane, Eiko ^{[10
]}

Shimada, Kazuaki ^{[11
]}

Furukawa, Tetsuya ^{[12
]}

Hashimoto, Hironobu ^{[12
]}

Maeda, Makoto ^{[12
]}

Sato, Tetsufumi ^{[13
]}

Sekimoto, Asuko ^{[14
]}

Sasaki, Chiyuki ^{[14
]}

Saito, Eiko ^{[15
]}

Uezono, Yasuhito ^{[16
]}

Matsuoka, Hiromichi ^{[1
,17
]}

机构：

[1] Natl Canc Ctr Japan, Natl Canc Ctr Hosp, Dept Psychooncol, Tokyo, Japan

[2] Juntendo Univ, Nerima Hosp, Dept Psychiat, Tokyo, Japan

[3] Tohoku Univ, Div Biostat, Grad Sch Med, Sendai, Miyagi, Japan

[4] Natl Canc Ctr Japan, Natl Canc Ctr East, Dept Psychooncol, Chiba, Japan

[5] Natl Hosp Org Kinki, Chuo Chest Med Ctr, Dept Psychosomat Internal Med, Osaka, Japan

[6] JORTC Data Ctr, NPO, Tokyo, Japan

[7] Natl Canc Ctr Japan, Inst Canc Control, Div Survivorship Res, Tokyo, Japan

[8] Nagoya City Univ, Grad Sch Med Sci, Dept Psychiat & Cognit Behav Med, Nagoya, Japan

[9] Natl Canc Ctr, Dept Expt Therapeut, Tokyo, Japan

[10] Natl Canc Ctr, Clin Trial Support Off, Tokyo, Japan

[11] Natl Canc Ctr, Natl Canc Ctr Japan, Tokyo, Japan

[12] Natl Canc Ctr Japan, Natl Canc Ctr Hosp, Dept Pharm, Tokyo, Japan

[13] Natl Canc Ctr Japan, Dept Anesthesia & Intens Care, Tokyo, Japan

[14] Natl Canc Ctr Japan, Natl Canc Ctr Hosp, Dept Nursing, Tokyo, Japan

[15] Inst Global Hlth Policy Res, Natl Ctr Global Hlth & Med, Bur Int Hlth Cooperat, Tokyo, Japan

[16] Jikei Univ, Sch Med, Dept Pain Control Res, Tokyo, Japan

[17] Natl Canc Ctr, Dept Psychooncol, 5-1-1 Tsukiji,Chuo Ku, Tokyo, Japan

来源：

JAPANESE JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 53卷 / 09期

关键词：

ramelteon; delirium; randomized controlled trial; cancer; JAPANESE VERSION; RATING-SCALE; VALIDATION; REVISED-98;

D O I：

10.1093/jjco/hyad061

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Postoperative delirium is an important issue in cancer patients, affecting surgical outcomes and the quality of life. Ramelteon is a melatonin receptor agonist with high affinity for MT1 and MT2 receptors. Clinical trials and observational studies in Japan, including in surgical cancer patients, have shown efficacy of ramelteon in delirium prevention, with no serious safety concerns. However, clinical trials from the USA have reported conflicting results. A Japanese phase II study investigated the efficacy and safety of ramelteon for delirium prevention following gastrectomy in patients aged >= 75 years, with findings suggesting the feasibility of a phase III trial. The aim of this multi-centre, double-blind, randomized placebo-controlled phase III trial is to evaluate the effectiveness and safety of oral ramelteon for postoperative delirium prevention in cancer patients aged >= 65 years as advanced medical care. The trial protocol is described here. This paper describes the protocol of a multi-centre, double-blind, randomized placebo-controlled trial evaluating the effectiveness and safety of oral ramelteon for postoperative delirium prevention in cancer patients aged >= 65 years.

引用

页码：851 / 857

页数：7

共 50 条

[41] A phase 2a, randomized, double-blind, placebo-controlled, single ascending-dose study to evaluate the safety and efficacy of naldemedine in patients with chronic non-cancer pain and opioid-induced bowel dysfunction
Webster, L.
Nagata, T.
Yamada, T.
Ferreira, J. Arjona
JOURNAL OF PAIN, 2016, 17 (04): : S94 - S94
[42] The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2 × 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients
Marilena Petrera
Laura Paleari
Matteo Clavarezza
Matteo Puntoni
Silvia Caviglia
Irene Maria Briata
Massimo Oppezzi
Eva Mihajlovic Mislej
Borut Stabuc
Michael Gnant
Thomas Bachleitner-Hofmann
Wilfried Roth
Dominique Scherer
Walter-E. Haefeli
Cornelia M. Ulrich
Andrea DeCensi
BMC Cancer, 18
[43] Efficacy and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes: DEFEND-2, a randomized, placebo-controlled, double-blind, multi-centre study
Ambery, P.
Donner, T. W.
Biswas, N.
Donaldson, J.
Parkin, J.
Dayan, C. M.
DIABETIC MEDICINE, 2014, 31 (04) : 399 - 402
[44] A phase II prospective, randomized, double-blind, placebo-controlled multi-centre clinical trial to assess the safety of 0.005% estriol vaginal gel in hormone receptor-positive postmenopausal women with early stage breast cancer in treatment with aromatase inhibitors (AIs) in the adjuvant setting - Initial safety results
Sanchez Rovira, P.
Gil Gil, M.
Presa Lorita, J.
Suarez Almarza, J.
Nieto Magro, C.
EUROPEAN JOURNAL OF CANCER, 2016, 57 : S44 - S44
[45] A Phase III, Randomized, Double-Blind, Placebo-Controlled Registration Trial To Evaluate the Efficacy and Safety of Pertuzumab plus Trastuzumab plus Docetaxel vs. Placebo plus Trastuzumab plus Docetaxel in Patients with Previously Untreated HER2-Positive Metastatic Breast Cancer (CLEOPATRA)
Baselga, J.
Kim, S-B
Im, S-A
Hegg, R.
im, Y-H
Roman, L.
Pedrini, J. L.
Cortes, J.
Knott, A.
Clark, E.
Ross, G. A.
Swain, S. M.
CANCER RESEARCH, 2011, 71
[46] The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2x2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients
Petrera, Marilena
Paleari, Laura
Clavarezza, Matteo
Puntoni, Matteo
Caviglia, Silvia
Briata, Irene Maria
Oppezzi, Massimo
Mislej, Eva Mihajlovic
Stabuc, Borut
Gnant, Michael
Bachleitner-Hofmann, Thomas
Roth, Wilfried
Scherer, Dominique
Haefeli, Walter-E.
Ulrich, Cornelia M.
DeCensi, Andrea
BMC CANCER, 2018, 18
[47] THE IDEAL STUDY: A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF THE ORAL α4β7 INTEGRIN PEPTIDE ANTAGONIST PN-943 IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
Plevy, Scott E.
Panes, Julian
D'Haens, Geert R.
Jairath, Vipul
Feagan, Brian G.
Gupta, Suneel K.
Hwang, C. C.
Sands, Bruce E.
Armuzzi, Alessandro
Reinisch, Walter
Schreiber, Stefan
Sandborn, William J.
GASTROENTEROLOGY, 2022, 162 (07) : S1394 - S1395
[48] Multi-center, randomized, double-blind, placebo-controlled, exploratory study to evaluate the efficacy and safety of HAD-B1 for dose-finding in EGFR positive and locally advanced or metastatic NSCLC subjects who need Afatinib therapy Study protocol clinical trial (SPIRIT Compliant)
Park, So-Jung
Kang, Hwi-Joong
Jun, Hyung-Joon
Shin, Seong-Hoon
Yoo, Hwa-Seung
MEDICINE, 2020, 99 (04)
[49] The World Health Organization Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns (ACTION-III) Trial: study protocol for a multi-country, multi-centre, double-blind, three-arm, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at high probability of late preterm birth in hospitals in low-resource countries
Adegboyega, Temitope Adesiji
Adejuyigbe, Ebunoluwa Aderonke
Adesina, Olubukola Adeponle
Adeyemi, Babalola
Ahmed, Salahuddin
Akinkunmi, Francis
Aluvaala, Jalemba
Anyabolu, Henry
Ariff, Shabina
Arya, Sugandha
Awowole, Ibraheem
Ayede, Adejumoke Idowu
Babar, Neelofur
Bachani, Sumitra
Bahl, Rajiv
Baqui, Abdullah H.
Chellani, Harish
Chowdhury, Saleha Begum
Coppola, Lynn M.
Cousens, Simon
Debata, Pradeep K.
de Costa, Ayesha
Dhaded, Sangappa M.
Donimath, Kasturi V.
Falade, Adegoke Gbadegesin
Goudar, Shivaprasad S.
Gupta, Shuchita
Gwako, George N.
Irinyenikan, Theresa Azonima
Isah, Dennis Anthony
Jabeen, Nigar
Javed, Arshia
Joseph, Naima T.
Khanam, Rasheda
Kinuthia, John
Kuti, Oluwafemi
Lavin, Tina
Laving, Ahmed R.
Maranna, Sandhya
Minckas, Nicole
Mittal, Pratima
Mohan, Diwakar
Nausheen, Sidrah
Nguyen, My Huong
Oladapo, Olufemi T.
Olutekunbi, Olanike Abosede
Oluwafemi, Rosena Olubanke
Osoti, Alfred
Pujar, Yeshita V.
Qureshi, Zahida P.
TRIALS, 2024, 25 (01)
[50] Rationale and design of the EMBRACE STEMI Study: A phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and efficacy of intravenous Bendavia on reperfusion injury in patients treated with standard therapy including primary percutaneous coronary intervention and stenting for ST-segment elevation myocardial infarction
Chakrabarti, Anjan K.
Feeney, Kristin
Abueg, Cassandra
Brown, David A.
Czyz, Ewa
Tendera, Michal
Andras Janosi
Giugliano, Robert P.
Kloner, Robert A.
Weaver, W. Douglas
Bode, Christoph
Godlewski, Jacek
Bela Merkely
Gibson, C. Michael
AMERICAN HEART JOURNAL, 2013, 165 (04) : 509 - +

← 1 2 3 4 5 →